Clostridium difficile infection (CDI) has increased in incidence and severity, and is now
among the most common nosocomial infections. Several agents are available for the initial …

Opinion statement Clostridium difficile infection (CDI) has been identified as a significant
threat to human health in the twenty-first century. Patients with CDI experience diarrhea …

Recurrent Clostridium difficile infection (CDI) is a perpetual problem that leads to increased
economic burden, higher healthcare cost, and significant morbidity and mortality. Its …

Clostridium difficile infection (CDI) is a potentially fatal illness, especially in the elderly and
hospitalized individuals. The recurrence and rates of CDI are increasing. In addition, some …

Despite intense international attention and efforts to reduce its incidence, Clostridium difficile
infection (CDI) remains a significant concern for patients, clinicians, and healthcare …

Background: Clostridium difficile infection (CDI) is one of the most common healthcare-
associated infections (HAI) in the United States and Canada, and incidence rates have …

Clostridium difficile infections: update on new European recommandations While
metronidazole and vancomycin have been the only drug options to date for the treatment of …

Metronidazole and vancomycin remain the front‐line therapies for most Clostridium difficile
infections (CDI). However, recurrent CDI occurs in∼ 25% of patients, causing significant …

Research and innovation around Clostridium difficile infection (CDI) has been a
multidisciplinary endeavor since discovery of the organism in 1978. The field of …

Clostridium difficile was first described as a cause of diarrhea in 1978 and is now among the
leading 3 hospital-acquired infections in the United States, along with methicillin-resistant …